EGFR and non-small cell lung carcinoma: Similar to fatal pneumonitis, interstitial lung disease (ILD) have also been represented in advanced NSCLC patients treated with EGFR-TKIs (gefıtinib: 3.5%; erlotinib: about 1.6%-4.5%) [43, 44] and with chemotherapy (docetaxel: 4.6%; gemcitabine: < 1%) [45–47].